Valeritas, Inc. is a medical device company focused on the development and commercialization of wearable insulin delivery solutions for adults with diabetes. The company’s flagship product, V-Go®, is a simple, disposable device that delivers a continuous basal rate of insulin over 24 hours and allows on-demand bolus dosing. Designed for patients with type 2 diabetes who require insulin therapy, V-Go supports flexible dosing and aims to improve adherence and glycemic control through its discreet, patch-like design.
V-Go received U.S. Food and Drug Administration (FDA) clearance and was launched commercially in the United States in 2013. The device is filled by specialty pharmacies with rapid-acting insulin and does not require batteries or electronics, which simplifies training for both patients and healthcare providers. In addition to the delivery device itself, Valeritas offers patient support services, including a dedicated customer care team, reimbursement assistance, and educational materials to help patients and clinicians integrate V-Go into diabetes management plans.
In recent years, Valeritas has expanded its offering to include digital health capabilities designed to enhance patient engagement and data sharing. The company’s platform enables secure transmission of dosing information to healthcare professionals, facilitating remote monitoring and personalized treatment adjustments. These digital tools are intended to complement the core V-Go system, offering a more comprehensive approach to insulin therapy management.
Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas operates primarily in the United States. The company is led by Chairman and Chief Executive Officer Dan Maziarz, supported by a management team with expertise in medical devices, endocrinology, and commercial operations. Valeritas continues to focus on innovation in insulin delivery and digital health to address the evolving needs of patients with diabetes.
AI Generated. May Contain Errors.
